Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WASHINGTON, Nov. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2021. "Vanda is approaching another pivotal moment in its 18-year history with the upcoming completion of the Phase III study of tradipitant in gastroparesis and anticipated results by the end of this year.

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

Vanda Pharmaceuticals Earnings Preview

WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 3, 2021, during which management will discuss the third quarter 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release

WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D.

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vanda (VNDA) Upgraded to Buy: Here's Why

WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021.

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint.

Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients

Vanda (VNDA) Upgraded to Buy: What Does It Mean for the Stock?

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2021 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 6.25% year over year to $0.17, which beat the estimate of $0.14.

Vanda Pharmaceuticals: Q2 Earnings Insights

WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021. "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs.

Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results

WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 28, 2021, during which management will discuss the second quarter 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021

Vanda (VNDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vanda (VNDA) Moves 5.8% Higher: Will This Strength Last?

Vanda Pharmaceuticals is enjoying steady sales growth from its two approved medicines, Hetlioz and Fanapt.Despite increasing revenues, Vanda is pushing aggressively for additional growth through label expansions.

Vanda: An Enticing Entry Point

WASHINGTON, May 12, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the following investor conferences: Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 AM ET. Oppenheimer Virtual Rare & Orphan Disease Summit on Friday, May 21, 2021 at 2:05 PM ET.

Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences

Amazon

Caterpillar

Disney

Electronic Arts

American Water Works

Mimecast

With the trading day about halfway over, the markets were getting crushed. The Nasdaq was again facing the worst of this, with the index down about 2%.

Amazon, Caterpillar, Disney, EA, Target and More Wednesday Afternoon Analyst Calls

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q1 2021 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue Estimates

WASHINGTON, May 5, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2021. "Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael H.

Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

WASHINGTON, April 20, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, May 5, 2021, during which management will discuss the first quarter 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA)

News for Vanda Pharmaceuticals Stock (VNDA)